Morgan Stanley Downgrades Epizyme (EPZM) to Equalweight, Following Earnings, CEO Succession
Tweet Send to a Friend
Morgan Stanley analyst David N. Lebowitz downgraded Epizyme (NASDAQ: EPZM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
